Extract

The primary objective is to compare the time to progression (TTP) of three daily doses of thalidomide (100, 200 and 400 mg) with high-dose dexamethasone in relapsed refractory multiple myeloma (MM) patients and to subsequently select the optimum thalidomide dose in terms of median TPP and toxicity.

Inclusion criteria

• Multiple myeloma

Country

• Bulgaria
• Croatia
• Czech Republic
• France
• Germany
• Hungary
• India
• Italy
• Philippines
• Poland
• Portugal
• Serbia
• Slovakia
• South Africa
• United Kingdom

Links

• nct
• ictrp